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IL-1 is one of the cytokines involved in joint diseases such as osteoarthritis. IL-1 plays a role in 
maintaining the balance of proteolytic proteins: MMPs and TIMPs inhibitors. Increased expression 
and uncontrolled IL-1 activity tend to increase the role of MMPs in degrading proteoglycans and joint 
tissue collagen. This study aims to reveal the interaction model of one of the osteoarthritis drugs, 
namely diacerein. A drug belongs to a group of disease-modifying osteoarthritis drugs (DMOADs) to 
suppress the development of the disease rate, improving the structure and function of the cartilage and 
surrounding tissue. "In silico" digital test uses the technique of "molecular docking: used as a method 
of the approach using the MOE 2007.09 software application. The test material was in the form of a 
diacerein 3D structure and five control ligands, while the IL-1β / IL-1RI receptor template was 
downloaded from pdb.org (PDB ID: 1ITB). The ligand pharmacokinetic profile will also be displayed 
obtained through the ADMETSAR server. The docking results showed diacerein had the lowest 
docking score of -12.3285 kcal/mol with the strongest affinity, the best pharmacokinetic profile but 
more toxic. This study proves that the mechanism of diacerein inhibition of IL-1β / IL-1RI receptors is 
similar to dexamethasone, prednisolone, and minocycline. 
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Osteoarthritis is an inflammatory disease of the knee, hip, and finger joints characterized by the 
occurrence of degradation and inflammation of connective tissue, joint-prone layers, synovium, and 
subchondral bone. The pathogenesis involves many genes: Tumor necrosis factor-alpha (TNF-α), 
Interleukin-1 (IL-1), and Interleukin-6 (IL-6) are several included genes (Fernández-moreno et al., 
2008). 
IL-1 is activated by several proinflammatory cytokine production lines such as p38 Mitogen-
Activated Protein Kinase (MAPK), Extracellular signal Regulated Kinases (ERK), Protein Kinase C 
(PKC), Nuclear Factor Kappaβ (NF-kβ) (Weber et al., 2014) (Sripathy et al., 2012). IL-1 plays a role 
in regulating MMP catalyst enzymes and TIMPs inhibitors; the condition of osteoarthritis occurs 
characterized by an increase in uncontrolled IL-1 activity so that MMP expression increases. IL-1β, 
one of the IL-1 family, is the main cytokine that stimulates COX-2 expression during inflammation 
(Halim and Jawad, 2015; Hopade et al., 2015). 
Diacerein is one of the drugs, included in the disease-modifying osteoarthritis drug group 
(DMOADs), which aims to suppress the development of the disease rate, improving the structure and 
function of the cartilage and surrounding tissue (Sofia et al., 2018). Diacerein has a rhein structure, 
which is a molecule with anthraquinonic ring. This structure is known to have anti-inflammatory 
activity by inhibiting interleukin-1, a cytokine that is highly involved in cartilage's degenerative 
process. This inhibition has been confirmed in vitro and in vivo (Martel-pelletier and Pelletier, 2010). 
Diacerein has been shown to be able to suppress the activity of catalytic protein MMPs, on the 
contrary, increase the expression and function of TIMPs in primary cells of osteoarthritis patients 
(Sofia et al., 2018). This effect is thought to occur through an inhibitory mechanism of IL-1 function 
and expression. Therefore it is necessary to prove with the in silico method or what is known as digital 
experiments through molecular docking techniques. This method is commonly used as a first step in 
cutting procedures for clinical trials to be directed and more efficient. 
In this study, the molecular docking diacerein aimed to confirm its inhibitory mechanism 
against IL-1 receptors, one of the target proteins for patients with OA. ADME toxicity prediction is 
done to compare the adsorption profile, distribution, metabolism, excretion, and toxicity of diacerein 
with other compounds that have the same target protein. 
 
MATERIALS AND METHODS 
Materials 
Pharmacokinetic profiles were predicted using the ADME-Toxicity method through the 
ADMETSAR server (http://lmmd.ecust.edu.cn:8000/predict/) (Awaluddin et al., 2017). The series of 
processes and visualization of docking results are done through the MOE software application. The 
observed compound was diacerein, a drug that has been used to treat osteoarthritis; while the control 
compounds include dexamethasone, prednisolone, colchicine, minocycline, chloroquine. The template 




The pharmacokinetic profile of all ligands was predicted in silico through the ADME-Toxicity 
method, which included observations of predicted adsorption, metabolic, distribution, excretion, and 
toxicity values. Then proceed with observations of the prediction of the affinity of all these ligands 
through molecular docking techniques. Before the molecular docking process is carried out, both 
ligands and enzymes are prepared and optimized for their 3-dimensional structure by adding hydrogen, 
removing water molecules, adding partial charges, and minimizing energy. After the process is 
completed, the site binding selection is based on articles (Halim and Jawad, 2015) through the MOE 
default system. Then proceed with the docking process through site binding that has been designed. 
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The docking receptor-ligand complex is stored in the PDB format, while the docking value is stored in 
the MDB format. The docking results are then analyzed, visualized by the 2D structure through 
LigPlot and the 3D structure using the MOE software application. 
 
RESULTS AND DISCUSSION 
Prediction of ligand pharmacokinetic profile 
ADMET evaluation is needed to determine the pharmacokinetic profile of a drug compound. 
The evaluation includes identification of adsorption, distribution, metabolism, excretion, and toxicity. 
All pharmacokinetic parameters are shown in Tables 1, 2, and 3 below. 
 
Table 1. Predicted results of adsorption and bioavailability parameters of test and control 
ligands 
Parameter Dx Pr Co Mi Ch Di 
Blood Barrier Brain + + + - + + 
Human Intestinal Absorption + + + + + + 
Caco-2 Permeability + - + + + + 
P-glycoprotein substrate S S NS S S NS 
P-glycoprotein inhibitor NI NI NI NI NI NI 
Renal organic cation transporter   NI NI NI NI NI NI 
LogP 1.0834 0.8616 1.1788 0.7775 0.8736 0.6674 
TPSA (Å) 94.83 94.83 83.09 164.63 28.16 124.04 
*Note 
Dx = Dexamethasone  S = Substare 
Pr = Prednisolone  NS = Non Substrate 
Co = Colchicine  NI = Non Inhibitor 
Mi = Minocyline 
Ch = Chloroquine 
Di = Diacerein 
 
 
Table 2. Predicted results of test and control ligand metabolism parameters 
Parameter Dx Pr Co Mi Ch Di 
CYP450 2C9 Substrate NS NS NS NS NS NS 
CYP450 2D6 Substrate NS NS NS NS S NS 
CYP450 3A4 Sunstrate S S S S S NS 
CYP450 1A2 Inhibitor NI NI NI NI NI I 
CYP450 2C9 Inhibitor NI NI NI NI NI NI 
CYP450 2D6 Inhibitor NI NI NI NI NI NI 
CYP450 2C19 Inhibitor NI NI NI NI NI NI 
CYP450 3A4 Inhibitor NI NI NI NI NI NI 
*Note 
S = Substrate 
NS = Non Substrate 
I = Inhibitor 
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Table 3. Predicted results of test and control ligand toxicity 
Parameter Dx Pr Co Mi Ch Di 
AMES Toxicity NT NT NT NT T T 
Carcinogens NC NC NC NC NC NC 
Fish Toxicity HT HT HT HT HT HT 
Tetrahymena Pyriformis Toxicity HT HT HT HT HT HT 
Honey Bee Toxicity HT HT LT LT LT HT 
Toxicity Level  III  III  III  III  II  II 
*Note 
NC = Non Carcinogen  HT = High Toxic 
T = Toxic  LT = Low Toxic 
NT = Non Toxic         II, III = Toxicity category according to Indonesian pharmacopoeia IV 
I = Inhibitor   
NI = Non-Inhibitor  
 
 
Each drug compound has physicochemical characteristics that affect its pharmacokinetic profile. 
The process of adsorption of compounds is influenced by several factors, such as lipophilicity, 
hydrogen bonds, molecular size, and pKa charge (Lawson et al., 2013). Drug compounds ideally have 
physicochemical properties balanced between their hydrophilicity and lipophilicity so they can 
penetrate the cell membrane and bind to the target receptor. Cell membranes tend to be lipophilic 
because of their phospholipid content, whereas cytosols tend to be hydrophilic in nature that contains 
protein and water.  
The partition coefficient (Log P) and Topological Polar Surface Area (TPSA) are the parameters 
used to assess compound lipophilicity. Log P is one of the lipophilic parameters to show the condition 
of the existence of drug molecules in nonpolar and polar solvents. Meanwhile, the Topological Polar 
Surface Area (TPSA) is a descriptor that was shown to correlate well with passive molecular transport 
through membranes. Log P value of natural compounds with value <5 is known to be an acceptable 
limit, while TPSA of ≤ 140 Å can be said to have Good bioavailability (Malik et al., 2019). Diacerein 
used in this study met the requirements as lipophilic compounds because it had log P (0.6674) and 
TPSA (124.04 Å) (Table 1). These two parameters can explain that oral absorption of diacerein 
through the gastrointestinal meets good absorption criteria. 
Diacerein also inhibits the activity of one of the cytochrome P450 (CYP450 1A2) metabolic 
enzymes (Table 2), which will cause changes in the concentration of other drugs metabolized by this 
enzyme. Hence, consideration needs to be given when administering a combination of drugs. 
Diacerein is also not a substrate of Pgp protein. Pgp is a protein transporter that works as a "drug 
efflux" that immediately ejects back compounds that enter the cell to the outside of the cell. The 
intracellular concentration of these compounds becomes low. This condition causes the drug's 
effectiveness to be suboptimal, triggering resistance and unexpected side effects (Siddik, 2003; 
Svetlana et al., 1998). In breast cancer cases, ± 50% resistance was reported due to the role of this Pgp 
protein (Bansal et al., 2014). The use of doxorubicin as first-line chemotherapy for breast cancer 
apparently triggers resistance through overexpression of Pgp protein (Bao et al., 2012). In joint disease 
cases, some anti-inflammatory drugs are also known to be a substrate of Pgp. Methotrexate, 
leflunomide, azathioprine, auranofin, and glucocorticoid classes are some of the anti-inflammatory 
drugs identified as substrate Pgp. The intracellular concentrations of all these drugs are low due to Pgp 
cells being pumped out immediately. This condition causes "impaired drug uptake" events (Jensen et 
al., 2003). 
  
Pharmaciana ISSN: 2088 4559; e-ISSN: 2477 0256  
 






In diacerein, this condition will not occur so that treatment can be done optimally, and the risk 
of resistance can be avoided. But even though diacerein turned out to be a relatively lower level of 
safety compared to the control ligand compound dexamethasone, prednisolone, minocycline, and 
colchicine (Table 3). 
 
Prediction of affinity through the molecular docking method 
Before the molecular docking process is done, two potential site bindings are obtained based on 
the default MOE tracking system. Docking scores of diacerein and five control ligand compounds 
(dexamethasone, prednisolone, colchicines, minocycline, and chloroquine) show a strong enough 
affinity for IL-1β / IL-1RI receptors (PDB code. 1ITB). All of them showed a tendency to release 
energy when forming complexes with IL-1β / IL-1RI receptors, but their affinity strength was 
different. The more negative the docking score obtained indicates its stronger affinity with the receptor 
(Frengki et al., 2018). Diacerein showed the strongest affinity marked by the docking score of -
12.1669 kcal/mol at site binding A and -11.3525 kcal/mol at site binding B. Then, successive 
dexamethasone, prednisolone, colchicine, minocycline, and chloroquine sites with score docking 
scores were followed. Each of -10.3866 kcal/mol, -10.5626 kcal/mol, -10.3809 kcal/mol, -11.3506 
kcal/mol and -9.9317 kcal/mol. The complete results of the docking are shown in Table 4. 
 
Table 4. Molecular Docking Results of diacerein and five control ligands at the site binding "A" 
and "B" receptor target (PDB: 1ltb) 
Site Binding "A" 
  Docking results Hydrogen-Bond Bond distance 
Dexamethason -10.3866 Lys 114 H-Don 
Thr 147 H-Don 
Ser 13   H-Don 





Prednisolone -10.5626 Asp 12  H-Don 
Ser 13   H-Don 
Thr 147 H-Don 
Gly 122 H-Acc 






Minocycline -11.3506 Arg 163 H-Acc 2.82 
Chloroquine -9.9317   
Diacerein -12.3285 Arg 11  H-Acc 2.17 
Site Binding "B" 
Colchicine -10.3809 Gln15  H-Acc 
Thr 147 H-Acc 
Thr 147 H-Acc 
Arg 163 H-Acc 






Diacerein -11.3525 Ser 13    H-Don 
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Figure1. 2D dan 3D structure of diacerein after docking at the site binding "A" and "B" 
receptor target (PDB: 1ltb) 
 
These docking results are in line with Halim and Jawad's (2015) report at the same binding site 
residues except in colchicine ligands. Ser 13, Thr 147, and Arg 163 residues are most commonly 
identified as interacting with IL-1β / IL-1RI receptors (PDB: 1ITB) to form hydrogen bonds, while 
(Halim and Jawad, 2015) report does not explain the type of bonding of the complex formed. 
The diacerein test ligand has the same interaction pattern with the dexamethasone and 
prednisolone control ligands at binding site A and the minocycline control ligands at binding site B. It 
is suspected that diacerein has the same inhibitory mechanism as the three control ligand compounds 
in the IL-1 receptor. The strength of diacerein binds to IL-1β / IL-1RI receptor is better than the three 
control ligands (Table 4). Diacerein only forms 1 hydrogen bond with site binding "A" (Arg 163), 
while dexamethasone control forms 4 hydrogen bonds (Lys 114 residue, 2 Trr 147 and Ser 13). 
Likewise, prednisolone control forms 5 hydrogen bonds (Asp 12, 2Thr 147, Ser 13, and Gly 122). As 
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well as colchicine as a control on the site binding "B" which forms 5 hydrogen bonds (Gln 15, 2 Thr 
147 and 2 Arg 163). However, diacerein's affinity was stronger than the two controls, presumably due 
to the hydrophobic interaction between diacerein and IL-1β / IL-1RI receptors. This is marked by the 
"pocket" site binding area "A" and "B" covered by hydrophobic residues (green in 3D structure). 
 
CONCLUSION 
Diacerein showed a better pharmacokinetic profile compared to 5 compounds with the same 
target protein (IL-1β / IL-1RI receptor inhibitors). However, diacerein showed a tendency for toxic 
properties to be stronger. Diacerein also showed the best docking score than the five compounds that 
indicated the strongest affinity as IL-1β / IL-1RI receptor inhibitors. This in silico research confirms 
the role of diacerein as one of the drugs of choice to overcome osteoarthritis. 
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